ATE233279T1 - Spezifisch bindende agentien - Google Patents

Spezifisch bindende agentien

Info

Publication number
ATE233279T1
ATE233279T1 AT91308147T AT91308147T ATE233279T1 AT E233279 T1 ATE233279 T1 AT E233279T1 AT 91308147 T AT91308147 T AT 91308147T AT 91308147 T AT91308147 T AT 91308147T AT E233279 T1 ATE233279 T1 AT E233279T1
Authority
AT
Austria
Prior art keywords
human antibody
reshaped
specific binding
binding agents
hmfg1
Prior art date
Application number
AT91308147T
Other languages
English (en)
Inventor
Martine Elisa Verhoeyen
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE233279T1 publication Critical patent/ATE233279T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT91308147T 1990-09-07 1991-09-05 Spezifisch bindende agentien ATE233279T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019553A GB9019553D0 (en) 1990-09-07 1990-09-07 Specific binding agents

Publications (1)

Publication Number Publication Date
ATE233279T1 true ATE233279T1 (de) 2003-03-15

Family

ID=10681827

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91308147T ATE233279T1 (de) 1990-09-07 1991-09-05 Spezifisch bindende agentien

Country Status (18)

Country Link
US (2) US6204366B1 (de)
EP (1) EP0483961B1 (de)
JP (2) JP3514456B2 (de)
KR (1) KR930702526A (de)
AT (1) ATE233279T1 (de)
AU (1) AU653167B2 (de)
BG (1) BG60716B1 (de)
CA (1) CA2090961C (de)
DE (1) DE69133200T2 (de)
DK (1) DK0483961T3 (de)
ES (1) ES2193129T3 (de)
FI (2) FI113873B (de)
GB (1) GB9019553D0 (de)
HU (2) HUT67796A (de)
NO (2) NO314595B1 (de)
RO (1) RO113432B1 (de)
UA (1) UA46691C2 (de)
WO (1) WO1992004380A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0571613B1 (de) * 1991-12-13 2003-09-17 Xoma Corporation Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
AU5615594A (en) * 1992-11-13 1994-06-08 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
US6281335B1 (en) * 1993-10-08 2001-08-28 Coulter Corporation Hybridoma and anti-KC-4 humanized monoclonal antibody
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
AU6396494A (en) * 1992-11-16 1994-06-08 Cancer Research Fund Of Contra Costa Peptides and anti-sense peptides with broad neoplastic specificity
US5792852A (en) * 1992-11-16 1998-08-11 Cancer Research Fund Of Contra Costa Polynucleotides encoding modified antibodies with human milk fat globule specificity
JPH07203974A (ja) * 1994-01-13 1995-08-08 Tosoh Corp 癌特異的ムチンを認識する抗体の遺伝子断片等
EP0781847A1 (de) * 1995-11-06 1997-07-02 MERCK PATENT GmbH Humanisierter monoklonaler Antikörper
BR9815289A (pt) * 1997-11-14 2001-12-26 Euro Celtique Sa Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
AU4430701A (en) * 2000-04-03 2001-10-15 Antisoma Research Limited Compounds for targeting
AU2002307064A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
GB0200657D0 (en) * 2002-01-12 2002-02-27 Antisoma Plc Cancer treatment
WO2003102157A2 (en) * 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries
AU2003256566A1 (en) * 2002-07-16 2004-02-02 Stuart Bussell Methods to construct multimeric dna and polymeric protein sequences as direct fusions or with linkers
CA2534055A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
KR101920250B1 (ko) * 2010-10-13 2018-11-20 얀센 바이오테크 인코포레이티드 인간 온코스타틴 m 항체 및 이용 방법
JP2014510080A (ja) * 2011-03-09 2014-04-24 セントローズ， エルエルシー 細胞外標的化薬物複合体
RU2493165C1 (ru) * 2012-02-28 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок muc1, способ детекции белка muc1 с помощью наноантител
CA2872010C (en) 2012-04-30 2021-06-08 Biothera, Inc. Compositions and methods for .beta.-glucan immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988005054A1 (en) * 1987-01-07 1988-07-14 Imperial Cancer Research Technology Limited Probe
DE3853515T3 (de) * 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
JPH03503120A (ja) * 1988-02-08 1991-07-18 ジョン　ミュア　キャンサー　アンド　エージング　インスティチュート　ディビジョン　オブ　ジョン　ミュア　メモリアル　ホスピタル ヒトのガン細胞における新規なムチン様糖蛋白質表面抗原に特異的なモノクローナル抗体
EP0442926A1 (de) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptide
JPH02273195A (ja) * 1988-11-17 1990-11-07 Univ Melbourne ヒト多型性上皮ムチンと反応するモノクローナル抗体
US5075219A (en) * 1989-04-05 1991-12-24 John Muir Cancer & Aging Institute Monoclonal antibody which recognizes a specific glycoprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen
KR970007783B1 (ko) * 1989-11-17 1997-05-16 유니레버 엔 브이 특이적 결합제

Also Published As

Publication number Publication date
AU8495391A (en) 1992-03-30
NO930825D0 (no) 1993-03-05
FI930984A0 (fi) 1993-03-05
NO315239B1 (no) 2003-08-04
JP2003061689A (ja) 2003-03-04
US6204366B1 (en) 2001-03-20
EP0483961B1 (de) 2003-02-26
FI113873B (fi) 2004-06-30
WO1992004380A1 (en) 1992-03-19
NO20014822D0 (no) 2001-10-04
HU9300609D0 (en) 1993-05-28
DE69133200T2 (de) 2003-11-20
UA46691C2 (uk) 2002-06-17
HUT67796A (en) 1995-04-28
ES2193129T3 (es) 2003-11-01
DE69133200D1 (de) 2003-04-03
AU653167B2 (en) 1994-09-22
NO314595B1 (no) 2003-04-14
KR930702526A (ko) 1993-09-09
NO20014822L (no) 1993-05-05
CA2090961C (en) 2004-01-20
JPH06500468A (ja) 1994-01-20
BG60716B1 (en) 1996-01-31
NO930825L (no) 1993-05-05
EP0483961A1 (de) 1992-05-06
GB9019553D0 (en) 1990-10-24
FI114611B (fi) 2004-11-30
JP3514456B2 (ja) 2004-03-31
RO113432B1 (ro) 1998-07-30
DK0483961T3 (da) 2003-06-23
CA2090961A1 (en) 1992-03-08
BG97607A (bg) 1994-03-31
US20020086978A1 (en) 2002-07-04
FI930984A (fi) 1993-03-05

Similar Documents

Publication Publication Date Title
ATE233279T1 (de) Spezifisch bindende agentien
PT99934A (pt) Processo para a producao de um anticorpo anti-htnf alfa recombinante ou humanizado
FI840219A (fi) Human-humanhybridom foer neoplasmer.
BR9708910A (pt) Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
FI922220A (fi) Specifika bindemedel.
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
RU93033872A (ru) Связывающие агенты, антитела, клетки плазмиды, применение плазмид, днк, вариабельные области антител, композиция, применение связующих агентов
CA2259724A1 (en) Monoclonal antibody which is specific for activated coagulation factor vii, and its use
FR2697088B1 (fr) Anticorps monoclonaux pour le diagnostic différentiel de cancers épithéliaux dans des épanchements séreux, hybridomes les secrétant et kit de diagnostic.
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
DK1414859T5 (da) Monoklonale anti-SSRP-1-antistoffer og hybridomer som producerer antistofferne
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
DK182188A (da) Humant tumorassocieret antigen
MX9605330A (es) Metodos y composiciones para el tratamiento de glomerulonefritis y otras enfermedades inflamatorias.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0483961

Country of ref document: EP

EELA Cancelled due to lapse of time